The researchers investigated hepatocyte transplantation as a treatment for glycogen storage disease.
They reported their findings in the latest issue of the Lancet.
A 47-year-old woman, who had glycogen storage disease type 1a and severe fasting hypoglycemia, had 2 billion viable hepatocytes infused via an indwelling portal-vein catheter.
|9 months after transplantation, the patient could eat a normal diet.
This was followed by a triple immunosuppression regimen with mycophenolate mofetil, tacrolimus, and steroids.
The team found that, 9 months after transplantation, on only tacrolimus, the patient could eat a normal diet and could fast for 7 hours without experiencing hypoglycemia.
Professor Maurizio Muraca, of the Department of Medical and Surgical Sciences, at the University of Padua, concluded on behalf of the group, "Our results show that hepatocyte transplantation might be an alternative to liver transplantation in glycogen storage disease type 1a."